Potential of Interferon-?? in Solid Tumours
| Autor: | Sundar Santhanam, Marios P. Decatris, Kenneth J. O'Byrne |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Pharmacology
Oncology Cervical cancer medicine.medical_specialty business.industry Head and neck cancer General Medicine medicine.disease Minimal residual disease Breast cancer Internal medicine medicine Pharmacology (medical) Carcinoid tumour Sarcoma Ovarian cancer Lung cancer business Biotechnology |
| Zdroj: | BioDrugs. 16:349-372 |
| ISSN: | 1173-8804 |
| Popis: | The second part of this review examines the use of recombinant interferon-alpha (rIFNalpha) in the following solid tumours: superficial bladder cancer, Kaposi's sarcoma, head and neck cancer, gastrointestinal cancers, lung cancer, mesothelioma and ovarian, breast and cervical malignancies. In superficial bladder cancer, intravesical rIFNalpha has a promising role as second-line therapy in patients resistant or intolerant to intravesical bacille Calmette-Guerin (BCG). In HIV-associated Kaposi's sarcoma, rIFNalpha is active as monotherapy and in combination with antiretroviral agents, especially in patients with CD4 counts >200/mm(3), no prior opportunistic infections and nonvisceral disease. rIFNalpha has shown encouraging results when used in combination with retinoids in the chemoprevention of head and neck squamous cell cancers. It is effective in the chemoprevention of hepatocellular cancer in hepatitis C-seropositive patients. In neuroendocrine tumours, including carcinoid tumour, low-dosage ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|